Nature Reviews Drug Discovery contents January 2017 Volume 16 Number 1 pp 1-70

If you are unable to see the message below, click here to view.

Advertisement
January 2017 marks the 2nd anniversary of Nature Plants! Visit the journal to see what’s been publishing and submit your research.
TABLE OF CONTENTS
January 2017 Volume 16 Number 1		Advertisement
2015 2-year Impact Factor 47.120 Journal Metrics 2-year Median 31	In this issue Comment News and Analysis Research Highlights Analysis Reviews Correspondence Also this month  Featured article: A comprehensive map of molecular drug targets Rita Santos, Oleg Ursu, Anna Gaulton, A. Patrícia Bento, Ramesh S. Donadi, Cristian G. Bologa, Anneli Karlsson, Bissan Al-Lazikani, Anne Hersey, Tudor I. Oprea & John P. Overington	Genomics has met its match!  MEET METABOLON, GENOMICS' PERFECT COMPLEMENT Explore the relationship between genotype and phenotype with Metabolon?s revolutionary solutions. We turn data into actionable insight unlocking the full potential of the genome. See why genomics and metabolomics are better together. Download our eBook
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: Liquid biopsy: CTC-based classifier predicts chemo resistance in lung cancer Date: Thursday January 19 2017 Time: 8AM PST, 11AM EST, 4PM GMT, 5PM CET  Register for FREE Sponsored by:  Menarini Silicon Biosystems
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Focus on the neuroscience toolbox Nature Neuroscience presents a special focus issue on the neuroscience toolbox highlighting recent technological advances, approaches and collaborative initiatives that are enabling new avenues of research.  Access the Focus free online for six months Produced with support from:  The Kavli Foundation
Comment: Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS Francesc Artigas, Esther Schenker, Pau Celada, Michael Spedding, Laia Lladó-Pelfort, Noemi Jurado, Mercedes Núñez, Noemi Santana, Eva Troyano-Rodriguez, Maurizio S. Riga, Hanna van den Munkhof, Anna Castañé, Hamdy Shaban, Thérèse M. Jay, Anushree Tripathi, Bill P. Godsil, Claude Sebban, Jean Mariani, Philippe Faure, Samir Takkilah, Zoe A. Hughes, Chester J. Siok, Mihaily Hajos, Karsten Wicke, Natalia Gass, Wolfgang Weber-Fahr, Alexander Sartorius, Robert Becker, Michael Didriksen, Jesper F. Bastlund, Mark Tricklebank, Céline Risterucci, Andreas Meyer-Lindenberg & Adam J. Schwarz p1 | doi:10.1038/nrd.2016.205 Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Alzheimer amyloid hypothesis lives on Asher Mullard p3 | doi:10.1038/nrd.2016.281 Despite the failure of Eli Lilly's anti-amyloid antibody solanezumab in its latest phase III trial for Alzheimer disease, a bulging pipeline of amyloid-modulating candidates and novel clinical trial strategies still hold promise. PDF
3D cell technologies head to the R&D assembly line Katie Kingwell p6 | doi:10.1038/nrd.2016.282 Organs-on-chips and organoids are set to start addressing key drug discovery bottlenecks. PDF
NEWS IN BRIEF R&D returns continue to fall Asher Mullard p9 | doi:10.1038/nrd.2016.284 PDF
NEWS IN BRIEF Cures Act shakes up the FDA and NIH Asher Mullard p9 | doi:10.1038/nrd.2016.285 PDF
BIOBUSINESS BRIEFS Trial watch: Opportunities and challenges of the 2016 target landscape Kyle Lafferty-Whyte, David Mormeneo & Montse del Fresno Marimon p10 | doi:10.1038/nrd.2016.263 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q1 2017 Zara Fulton p11 | doi:10.1038/nrd.2016.267 PDF
AN AUDIENCE WITH John Lechleiter p12 | doi:10.1038/nrd.2016.277 John Lechleiter, the retiring Chief Executive Officer at Eli Lilly, discusses his path from the chemistry lab to the executive suite. PDF
FROM THE ANALYST'S COUCH Drug launch curves in the modern era Seth Robey & Frank S. David p13 | doi:10.1038/nrd.2016.236 The shape of the predicted sales launch curve can dramatically affect financial models of pre-commercial drugs. This article provides an update on a commonly used framework for modelling launch curves. PDF
RESEARCH HIGHLIGHTS Top Anticancer drugs: Cutting the antioxidant supply chain p15 | doi:10.1038/nrd.2016.274 PDF Drug delivery: Star-shaped pill sustains drug release p16 | doi:10.1038/nrd.2016.273 PDF Anticancer drugs: Switching off immune suppression p16 | doi:10.1038/nrd.2016.283 PDF Cancer: Microtubule-straightening compound widens the therapeutic window p17 | doi:10.1038/nrd.2016.275 PDF Diabetes: Turning down galectin 3 to combat insulin resistance p18 | doi:10.1038/nrd.2016.276 PDF IN BRIEF Cardiovascular disease: Dietary supplement protects the heart | Antibacterials: Microcins limit intestinal infection | Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans | Computational chemistry: Novel virtual screening approach PDF Nature Reviews Drug Discovery JOBS of the week Tenure-track Assistant Professor in Cancer Computational Biology Oregon Health & Science University (OHSU) School of Medicine More Science jobs from Nature Reviews Drug Discovery EVENT Antibodies in Drug Discovery 06.03.17 Cambridge, USA More science events from
Advertisement
Unexplored opportunities in the druggable human genome This poster presents a categorization of human proteins based on the amount of data on them, highlighting a knowledge deficit and indicating novel drug discovery opportunities.  Download the Poster free online Produced with support from: Illuminating the Druggable Genome Knowledge Management Center  (IDG KMC)
ANALYSIS		Top
A comprehensive map of molecular drug targets Rita Santos, Oleg Ursu, Anna Gaulton, A. Patrícia Bento, Ramesh S. Donadi, Cristian G. Bologa, Anneli Karlsson, Bissan Al-Lazikani, Anne Hersey, Tudor I. Oprea & John P. Overington p19 | doi:10.1038/nrd.2016.230 The success of mechanism-based drug discovery depends on the definition of the drug target, but targets are often poorly defined in the literature. Here, Overington and colleagues present a comprehensive map of the molecular targets of approved drugs, and explore aspects including the footprint of target classes across disease areas, the success of privileged target families and drug target orthologues across standard model organisms. Abstract | Full Text | PDF | Supplementary information
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: CRISPR/Cas9 strategies for disease modeling and drug discovery Date: Tuesday, 24 January 2017 Time: 8AM PST, 11AM EST, 4PM GMT, 5PM CST Register for FREE Sponsored by:  The Jackson Laboratory
REVIEWS		Top
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets Yufang Shi, Liming Du, Liangyu Lin & Ying Wang p35 | doi:10.1038/nrd.2016.193 Mesenchymal stem cells (MSCs) actively contribute to the formation of the tumour microenvironment by producing various factors that affect tumour growth and response to therapy. Moreover, MSCs can modulate tumour immunity. This Review discusses the various roles of MSCs in cancer and highlights potential strategies to target pro-tumorigenic activities of MSCs or take advantage of the tumour-homing capacity of MSCs for the delivery of drugs. Abstract | Full Text | PDF
Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases John A. Hamilton, Andrew D. Cook & Paul P. Tak p53 | doi:10.1038/nrd.2016.231 The colony-stimulating factors (CSFs) have roles in inflammation and immunity, and are potential targets for diseases caused by aberrant immune activation, including rheumatoid arthritis and multiple sclerosis. Hamilton et al. describe how distinguishing attributes could be used to target individual CSFs for therapeutic use in immune and inflammatory conditions and the progress that has been made towards that goal. They also clarify misconceptions about targeting this class of molecules. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine Kathleen M. Giacomini, Sook Wah Yee, Taisei Mushiroda, Richard M. Weinshilboum, Mark J. Ratain & Michiaki Kubo p70 | doi:10.1038/nrd.2016.234 Full Text | PDF | Supplementary information
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.